| Behzad Soufer, D.o., Apc | |
|
5000 Van Nuys Blvd Ste 201 Sherman Oaks CA 91403-1717 | |
| (818) 572-1490 | |
| (818) 572-1491 |
| Full Name | Behzad Soufer, D.o., Apc |
|---|---|
| Speciality | Family Medicine |
| Location | 5000 Van Nuys Blvd Ste 201, Sherman Oaks, California |
| Authorized Official Name and Position | Behzad Souferzadeh (DO/OWNER) |
| Authorized Official Contact | 8185721490 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Behzad Soufer, D.o., Apc 5000 Van Nuys Blvd Ste 201 Sherman Oaks CA 91403-1717 Ph: (818) 572-1490 | Behzad Soufer, D.o., Apc 5000 Van Nuys Blvd Ste 201 Sherman Oaks CA 91403-1717 Ph: (818) 572-1490 |
| NPI Number | 1245640671 |
|---|---|
| Provider Enumeration Date | 05/07/2014 |
| Last Update Date | 03/01/2024 |
| Medicare PECOS PAC ID | 6305061516 |
|---|---|
| Medicare Enrollment ID | O20140702000224 |
News Archive
Scientists at Duke University have created the first map of imprinted genes throughout the human genome, and they say a modern-day Rosetta stone – a form of artificial intelligence called machine learning – was the key to their success.
Allergan plc announced today the U.S. Food and Drug Administration has cleared the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) for use in the U.S.
A new study reports that the risk of transmitting SARS-CoV-2 through such fomites is very low.
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245640671 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 20A12379 (California) | Primary |
| Provider Name | Behzad Souferzadeh |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1851694988 PECOS PAC ID: 6507002979 Enrollment ID: I20130410000218 |
News Archive
Scientists at Duke University have created the first map of imprinted genes throughout the human genome, and they say a modern-day Rosetta stone – a form of artificial intelligence called machine learning – was the key to their success.
Allergan plc announced today the U.S. Food and Drug Administration has cleared the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) for use in the U.S.
A new study reports that the risk of transmitting SARS-CoV-2 through such fomites is very low.
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
› Verified 6 days ago
| Provider Name | Arash J Nikamal |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1427393784 PECOS PAC ID: 3971730573 Enrollment ID: I20170601002770 |
News Archive
Scientists at Duke University have created the first map of imprinted genes throughout the human genome, and they say a modern-day Rosetta stone – a form of artificial intelligence called machine learning – was the key to their success.
Allergan plc announced today the U.S. Food and Drug Administration has cleared the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) for use in the U.S.
A new study reports that the risk of transmitting SARS-CoV-2 through such fomites is very low.
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
› Verified 6 days ago
| Provider Name | Mordechai A Levin |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1699303701 PECOS PAC ID: 8325407174 Enrollment ID: I20230711003186 |
News Archive
Scientists at Duke University have created the first map of imprinted genes throughout the human genome, and they say a modern-day Rosetta stone – a form of artificial intelligence called machine learning – was the key to their success.
Allergan plc announced today the U.S. Food and Drug Administration has cleared the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) for use in the U.S.
A new study reports that the risk of transmitting SARS-CoV-2 through such fomites is very low.
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
› Verified 6 days ago
News Archive
Scientists at Duke University have created the first map of imprinted genes throughout the human genome, and they say a modern-day Rosetta stone – a form of artificial intelligence called machine learning – was the key to their success.
Allergan plc announced today the U.S. Food and Drug Administration has cleared the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) for use in the U.S.
A new study reports that the risk of transmitting SARS-CoV-2 through such fomites is very low.
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
› Verified 6 days ago
Gary Schneider D O Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4835 Van Nuys Blvd Ste 109, Sherman Oaks, CA 91403 Phone: 818-905-9586 Fax: 818-905-0130 | |
Joey Brett Md A Professional Medical Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 13320 Riverside Dr, Suite 104, Sherman Oaks, CA 91423 Phone: 818-789-0034 Fax: 818-789-0042 | |
Ali Sheybani Medical Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4955 Van Nuys Blvd, Suite 405, Sherman Oaks, CA 91403 Phone: 818-464-4870 Fax: 818-464-4877 | |
Alberto X. Campain, M.d., A Professional Medical Corporation Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4940 Van Nuys Blvd., Suite 200, Sherman Oaks, CA 91403 Phone: 818-528-1090 Fax: 818-528-1099 | |
Maximum Care Medical Center, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4910 Van Nuys Blvd, Suite 306, Sherman Oaks, CA 91403 Phone: 818-426-0886 | |
Peter P. Koenig, M.d., Incorporated Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4940 Van Nuys Blvd., Suite 200, Sherman Oaks, CA 91403 Phone: 818-528-1222 Fax: 828-528-1225 | |
Health West Medical Center, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 14417 Burbank Blvd, Sherman Oaks, CA 91401 Phone: 818-786-3318 |